Northwire Canada EditionSaturday, July 18, 2026
Sign inSubscribe
Northwire
⌕
AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0% AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0%

Healthcare

Page 108
  1. Nov 05, 2025 · 15:11 · APLI

    Appili Therapeutics arranges $750,000 private placement

    Appili Therapeutics arranges $750,000 private placement

    01
  2. Nov 05, 2025 · 11:02 · MBX

    Microbix faces ransomware attack, says no ops impact

    Microbix faces ransomware attack, says no ops impact

    02
  3. Nov 05, 2025 · 09:00 · OTC

    Ocumetics Reports Continued Improvement in First Group of Patients. Early Vision Results Surpass Expectations

    Ocumetics Reports Continued Improvement in First Group of Patients. Early Vision Results Surpass Expectations

    03
  4. Nov 05, 2025 · 08:30 · ARCH

    Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia

    Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia

    04
  5. Nov 05, 2025 · 07:46 · CRDL

    Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

    Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

    05
  6. Nov 05, 2025 · 07:30 · CTX

    Crescita Reports Third Quarter 2025 Results

    Crescita Reports Third Quarter 2025 Results

    06
  7. Nov 05, 2025 · 07:16 · APLI

    Appili Therapeutics Announces Proposed Non-Brokered Private Placement

    Appili Therapeutics Announces Proposed Non-Brokered Private Placement

    07
  8. Nov 05, 2025 · 07:00 · MBX

    Microbix Addresses Cybersecurity Incident

    Microbix Addresses Cybersecurity Incident

    08
  9. Nov 05, 2025 · 03:52 · NARA

    Pangenomic enters LOI for distribution deal with Ayla

    Pangenomic enters LOI for distribution deal with Ayla

    09
  10. Nov 04, 2025 · 23:53 · EPRX

    Eupraxia ends Q3 with cash of $89-million (U.S.)

    Eupraxia ends Q3 with cash of $89-million (U.S.)

    10
  11. Nov 04, 2025 · 23:20 · HEM

    Hemostemix closes $461,230 first tranche of financing

    Hemostemix closes $461,230 first tranche of financing

    11
  12. Nov 04, 2025 · 20:00 · NARA

    PanGenomic Health Signs Letter of Intent with Ayla BioScience

    PanGenomic Health Signs Letter of Intent with Ayla BioScience

    12
  13. Nov 04, 2025 · 18:01 · MYTC

    MyndTec Inc. Completes Seventh Tranche of Non-Brokered Private Placement

    MyndTec Inc. Completes Seventh Tranche of Non-Brokered Private Placement

    13
  14. Nov 04, 2025 · 17:50 · IOT

    Innovotech Inc. Reports Record Revenue For Its Third Quarter.

    Innovotech Inc. Reports Record Revenue For Its Third Quarter.

    14
← Newer Older →